AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05966493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Matching vehicle without lufepirsen.
Study NCT06435182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT202 conc 0.5%
Description: Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily
Study NCT06435182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT202 conc 0.1%
Description: Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily
Study NCT06435182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
Study NCT05034458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crohn's disease exclusion diet
Description: Patients will receive, in addition to their normal treatment, polymeric formula + diet
Study NCT05911464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10386
Description: Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
Study NCT06315244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US Guided Perineural Injection and Neuroprolotherapy
Description: Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.
Study NCT06315244 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: US Guided Perineural Injection and Neuroprolotherapy
Description: Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.
Study NCT06445894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossesous (FDI) muscle of the left motor cortex will be targeted using neuronavigation software.
Study NCT06445894 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
Study NCT05366192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir and ritonavir stage 1
Description: Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
Study NCT05366192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir and ritonavir stage 2
Description: Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
Study NCT06299813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentelan
Description: The experimental treatment group will be administered betamethasone 0.1 mg per kg.
Study NCT06299813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
Study NCT05596786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
Study NCT05596786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
Study NCT04430283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDY-5301
Description: FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
Study NCT04430283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.
Study NCT04944615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The guidewire successfully passed the CTO lesion
Description: The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery.
Study NCT05825599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl methylcellulose eye drops
Description: Hydroxypropyl methylcellulose (HPMC)-based eyedrops
Study NCT04693923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Description: Fluid challenge according to the assigned group
Study NCT04693923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid challenge
Description: Fluid challenge according to the assigned group
Study NCT04238988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
Study NCT05816694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB-Paclitaxel plus Cisplatin
Description: NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
Study NCT05816694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin plus Epirubicin plus Cyclophosphamide
Description: Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
Study NCT04238988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy medication
Study NCT06314165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music medicine practice
Description: Music medicine will be applied
Study NCT05597917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
Study NCT05597917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
Study NCT05597917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tTF-NGR
Description: Patients will receive standard trabectedin according to arm 1 plus the safe dose according to safety run-in part of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days, q d 22 x until disease progression or contraindications against further application.
Study NCT06315582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of uterine septum with hysteroscopic scissors without electrosurgery.
Description: Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue
Study NCT06315582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic septoplasty utilizing bipolar electrosurgery
Description: Hysteroscopic septoplasty utilizing bipolar electrosurgery
Study NCT05825196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: tumor tissue and blood tests
Description: In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
Study NCT04944615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The guidewire successfully passed the CTO lesion
Description: The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery.
Study NCT04238988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Chemotherapy medication
Study NCT05502965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary pattern
Description: Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
Study NCT05502965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEN
Description: All energy and nutrients are obtained from exclusive enteral nutrition.
Study NCT06092385 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Clinical assessment and blood sampling at day of inclusion and in 6- monthly intervals for stable cirrhotic patients; at day of inclusion and on days 3, 7, 14 and 28 for acute decompensation or acute-on-chronic liver failure patients; assessment of clinical, psychosocial/behavioural and patient-reported data in parallel with blood sampling;~* Biobanking of PBMCs and serum/plasma samples~* Biobanking of other biological material if sampled for clinical reasons (liver biopsies, ascites, urine, gut mucosa, lymph nodes)
Study NCT05249530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal adjustment
Description: Chiropractic spinal adjustment
Study NCT05249530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-force simulation
Description: Non-force simulation
Study NCT05698394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 0.2 mg/kg S-ketamine in 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth
Study NCT05698394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
Study NCT06622434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunization
Description: One month after completion of concurrent radiochemotherapy, patients will be immunized during the adjuvant phase of monthly temozolomide with subcutaneous injections of the vaccine formulation (D0, W2, W4, W6, and then every 2 months until progression) consisting of 2 tumor antigens (TERT and PTPRZ1) adjuvanted with synthetic melanin and a TLR9 agonist (CpG-ODN).
Study NCT06183489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab will be administered via a subcutaneous injection (SC)
Study NCT06630533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Exercise Group
Description: Baduanjin exercises (Eight-Part Exercises or Eight-Part Brocades), an important part of Qigong, consist of eight postures (1-holding the hands high with palms up, 2- posing as an archer shooting, 3- holding one arm aloft, 4- looking backwards, 5- swinging the head and lowering the body, 6- moving the hands down the back and legs and touching the feet, 7- thrusting the fists and making the eyes glare, and 8- raising and lowering the heels).
Study NCT06714695 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chitosan
Description: chitosan mouthwash
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-H2D3
Description: Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[68Ga\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-DOTA-H2D3 injection.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-RB14
Description: Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[18F\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RB14 injection.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-T4
Description: Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[68Ga\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-T4
Description: Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[18F\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-G5
Description: Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[68Ga\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-G5 injection.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-G5
Description: Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[18F\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-G5 injection.
Study NCT04938388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pill
Description: All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
Study NCT04938388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fresh organic vegetables
Description: Prescriptions of organic vegetables
Study NCT04938388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresh organic vegetables
Description: Prescriptions of organic vegetables
Study NCT04875624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)
Description: Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
Study NCT05486052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of reliability, repeatability and validity of devices among healthy subjects
Description: Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice
Study NCT05486052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training
Description: The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.
Study NCT05486052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.
Description: Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
Study NCT05877469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mat pilates Training
Description: In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
Study NCT05877469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Training
Description: In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-WWH347
Description: Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[68Ga\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-WWH347 injection.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-WWH347
Description: Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[18F\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-WWH347 injection.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-RND20
Description: Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[68Ga\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RND20 injection.
Study NCT06715839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-RND20
Description: Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[18F\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RND20 injection.
Study NCT06715046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collation for cfDNA methylation analysis
Description: Sample collation for cfDNA methylation analysis
Study NCT06715046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collection for EV phenotype analysis
Description: Analysis of the EV phenotype to evaluate their potential value as markers for GVHD, relapse and engraftment.
Study NCT04846387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained.
Study NCT05399030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-332
Description: ICP-332 will be administered as tablet
Study NCT05399030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablet
Study NCT05275452 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05651516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PI-2620 PET/CT
Description: PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.